Yarrow Bioscience raises ~$161.8M in public offering of common stock

VYNE Therapeutics Inc.

Sold 5,769,231 shares at $26.00/share; underwriters exercised full option for 865,384 additional shares.
Net proceeds expected ~$161.8M after underwriting discounts and estimated offering expenses.
Offer led by Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities; closing expected Sept 14, 2026.
Directors and executive officers subject to 60-day lock-up; shelf registration S-3 declared effective Aug 19, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.